Ecopipam

DB12273InvestigationalSmall molecule

Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.

Mechanism: Pharmacologically active on Dopamine receptor D1
Curator reviewed
Formula / weight: C₁₉H₂₀ClNO · 313.83 g/mol (avg)
Code names: SCH 39166

Resolves to

Compound

UNII0X748O646KCAS112108-01-7ChEMBLCHEMBL298406ChEBI93645PubChem107930

Structure

InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-NSMILES[H][C@]12CCC3=CC=CC=C3[C@]1([H])C1=CC(O)=C(Cl)C=C1CCN2C

Targets

P21728DRD1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

727Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ecopipam, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account